MedTrace Logo

Screening for Early Evidence of Diabetes

NCT00614783 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3478

Last updated 2012-12-04

No results posted yet for this study

Summary

This is a pivotal study to determine the accuracy of a new device (SCOUT) in screening persons for pre-diabetes or diabetes. SCOUT will be compared to the standard screening test (Fasting Plasma Glucose), using the Oral Glucose Tolerance Test as the reference standard.

SCOUT uses a rapid, noninvasive, light-based technology to measure the concentration of chemicals in the skin called advanced glycation endproducts (AGEs). Several studies have demonstrated that AGEs accumulate in skin faster in individuals with poor control of blood sugar.

Persons will be eligible for the study if they are 'at risk' for diabetes based on their age and other risk factors as defined by the American Diabetes Association.

Conditions

  • Diabetes Mellitus, Type 2

Sponsors & Collaborators

  • VeraLight, Inc.

    lead INDUSTRY

Principal Investigators

  • John Maynard, MS · Executive Vice President, VeraLight Inc.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-05-31
Primary Completion
2010-12-31
Completion
2010-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00614783 on ClinicalTrials.gov